Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Status:
Completed
Trial end date:
2018-10-12
Target enrollment:
Participant gender:
Summary
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the
activity and safety of PM01183 versus PLD or topotecan as control arm in patients with
platinum-resistant ovarian cancer. PM01183 will be explored as single agent in the
experimental arm (Arm A) versus PLD or topotecan in the control arm (Arm B).